Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.

TSXV:ARCH - Post by User

Arch Biopartners Inc > $3.35- Extremely Undervalued in Comparison to Phase II peers

<< Previous

Bullboard Posts

Next >>

Comment by C10H12N2on Dec 30, 2021 6:14pm

77 Views

Post# 34272384

RE:$3.35- Extremely Undervalued in Comparison to Phase II peers

I find it hilariously hypocritical that you would place Bellus Health in comparison to Arch and Arch is not chasing Chronic Cough. Yet an actual company with Chronic Cough in it's portfolio at Phase II and proven to be 110% better than the current leading Chronic Cough drug by Merck. That company is valued at U$S5M which is 790M $ less than your example. Yet, you ranted about Algernon Pharmaceuticals Six Ways To Sunday about it not being worth it’s current lousy valuation with absolutely ZERO real basis for your criticism other than trolling the message board about your coveted Arch stock pick. Do you want to know the truth of the matter about Algernon Pharmaceuticals which could potentially cover your coveted Arch as well? Here it is in plain and simple terms told by the CEO @ Algernon Pharmaceuticals:

The company listed on the Canadian Securities Exchange (CSE) has applied to list its common shares on the Nasdaq.

Algernon Chief Executive Officer Christopher J. Moreau said he thinks Nasdaq investors may be more knowledgeable and experienced in the pharmaceutical sector and will be more interested in what the company has to offer.

"The CSE is an excellent place for companies that need initial seed capital and for resource, mining and some tech deals," Moreau told Streetwise Reports. "But specifically, when it comes to pharmaceutical development, I don't personally believe it's that well understood [by] the Canadian investor community."

Co. Looks To US For Help Fighting Strokes

Riverfolk, you spew a lot of nonsense and you don't know what you are talking about regarding uplisting to Nasdaq. Take it from someone who actually lives in America and had 99.9% of my portfolio in the NAsdaq markets. You got thrown in jail on the CEO.CA, but you're free bird to do all the silly chirping you want. Yeah, Riverfolk is the guy who buys it all all the time. Stock up River buys. Stock down River buys. Yeah, I've heard it all before sport.